OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models.
Saved in:
| Title: | OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models. |
|---|---|
| Authors: | Estrada J; Amgen Inc, Thousand Oaks, California, USA., Zhan J; Amgen Inc, Thousand Oaks, California, USA., Mitchell P; Amgen Inc, Thousand Oaks, California, USA., Werner J; Amgen Inc, Thousand Oaks, California, USA., Beltran PJ; BridgeBio Pharma, Palo Alto, California, USA., DeVoss J; Amgen Inc, Thousand Oaks, California, USA., Qing J; BeiGene, Beijing, China., Cooke KS; Amgen Inc, Thousand Oaks, California, USA kcooke@amgen.com. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2023 May; Vol. 11 (5). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
